Japan Q3 Roundup: Forex Impacts Majors Amid New Product Growth Expectations

Leadership Changes Also Announced

Amid ongoing impact from exchange rates, Japan's five largest pharma firms showed mostly positive growth in the fiscal nine-month period. Enhertu will continue to drive Daiichi Sankyo, while Shionogi is forecasting record-breaking revenue on oral COVID-19 drug Xocova and Eisai is rolling out closely-watched Alzheimer's contender Leqembi.

Weaker forex rate of JPY still impacted all five pharmaceutical firms.
Weaker yen impacted Japan's top pharma firms in Q3 but mainstays strong • Source: Shutterstock

More from Business

More from Scrip